ArticleAnnals of surgical oncology2026
Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReal-world adjuvant systemic therapy (AST) use for eligible renal cell carcinoma (RCC) patients remains insufficiently characterized in the contemporary treatment era. In particular, it is unclear whether treatment allocation reflects established high-risk tumor characteristics.
methodsIn the Surveillance, Epidemiology, and End Results (SEER) database, the study identified patients eligible for AST after nephrectomy (2018-2022). Temporal trends in AST use were assessed. Multivariable logistic regression models tested associations between histopathologic high-risk features (T4 stage, tumor grade 4, and N1-2 stage) and AST use.
resultsOf 6,497 eligible patients, 1,163 (18%) received AST. Annual proportions of AST increased from 13% in 2018 to 36% in 2022. Higher AST use was independently predicted by T4 stage (33% vs. 18%; odds ratio [OR], 1.68; p = 0.006), tumor grade 4 (28% vs. 15%; OR, 1.94; p < 0.001), and N1-2 stage (36% vs. 17%; OR, 2.57; p < 0.001). Patients who had any of these three high-risk features were more likely to receive AST than those who did not (28% vs. 14%; OR, 2.27; p < 0.001). Moreover, a stepwise increase in AST use was observed with an increasing number of high-risk features (one: 26% [OR, 2.09; p < 0.001], two: 37% [OR, 3.56; p < 0.001], three: 40% [OR, 4.04; p = 0.014]).
conclusionsOnly a minority of eligible RCC patients received AST after nephrectomy. However, the proportion of AST use increased over time. Use of AST was strongly associated with adverse tumor characteristics. A stratification according to the number of high-risk features showed a dose-response effect. Nevertheless, AST use remained limited even among patients at the highest risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.